RE:RE:Tanzi just presented at a major conferenceFryinpan wrote: HenrySC ... this is an excellent point. Opportunity lost.
???????
TORONTO, Ontario and CAMBRIDGE, Mass. —June 5, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer’s disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world’s most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care. ProMIS’ Chief Development Officer Dr. Johanne Kaplan will present the company’s lead therapeutic candidate PMN310 which demonstrates high selectivity for the toxic forms of amyloid beta implicated as a root cause of Alzheimer’s disease.
In the poster, “Selective targeting of HHQK conformational epitope in amyloid-beta oligomer species by PMN310, a monoclonal antibody rationally designed for greater therapeutic potency in Alzheimer’s disease,” Dr. Kaplan will present data for PMN310 that show:
- Superior selectivity for amyloid beta (AOs) toxic oligomers.
- Potential to safely administer high doses of PMN310 with a reduced risk of brain swelling or ARIA.
- Potential to show greater therapeutic potency compared with other A-directed antibodies.